Department of Surgery, Ordensklinikum Linz, Linz, Austria; Johannes Kepler University Linz, Medical Faculty, Linz, Austria.
Department of Surgery, Ordensklinikum Linz, Linz, Austria.
J Vasc Surg. 2022 Aug;76(2):595-604.e1. doi: 10.1016/j.jvs.2022.02.029. Epub 2022 Mar 28.
Clostridium septicum bacteremia is often associated with occult malignancies (approximately 80%), especially of the right colon. Furthermore, inflammation of the aortic wall can rapidly lead to aneurysm induction through bacterial seeding into atheromatous lesions with consecutive life-threatening rupture. We summarize all published data on this rare and lethal disease to evaluate therapeutic approaches and give valid treatment recommendations because there are no guidelines.
A systematic review of the literature was conducted screening EMBASE and MEDLINE databases following the PRISMA guidelines with search period from first description to August 25, 2021.
There were 72 cases of C septicum aortitis reported in 64 publications. Endovascular aortic repair (EVAR) was performed in a minority of patients (n = 6) unfit for surgery but lacked long-term survivors. Antibiotic treatment was beneficial in a bridge to surgery concept, but up to now harbored a 6-month mortality rate of 100% (median overall survival, 0.5 months) when no additional aortic repair was performed. Open aortic repair was the only potential curative approach but was accompanied with a 90-day-mortality of 26.7% (4/15).
Open aortic repair combined with perioperative antibiotic treatment should be offered to all patients as the only potentially curative approach. If applicable, resection of a coexisting colonic tumor should be performed after successful aortic repair. Alternatively, long-term antibiotic treatment can be offered to patients unfit for surgery in a palliative setting. Endovascular aortic repair has been performed on a minority of patients with a high risk for stent graft infection and should remain a salvage strategy when therapeutic pressure demands acute intervention in patients unfit for surgery.
梭状芽孢杆菌菌血症常与隐匿性恶性肿瘤(约 80%)相关,尤其是右半结肠。此外,主动脉壁炎症可通过细菌播散至动脉粥样硬化病变,迅速导致动脉瘤形成,继而发生危及生命的破裂。我们总结了所有关于这种罕见且致命疾病的已发表数据,以评估治疗方法并提供有效的治疗建议,因为目前尚无指南。
按照 PRISMA 指南,对 EMBASE 和 MEDLINE 数据库进行系统文献回顾,检索时间从首次描述到 2021 年 8 月 25 日。
在 64 篇文献中报道了 72 例梭状芽孢杆菌性主动脉炎病例。少数(n=6)不适合手术的患者进行了血管内主动脉修复(EVAR),但缺乏长期存活者。抗生素治疗在手术桥接概念中是有益的,但迄今为止,如果不进行额外的主动脉修复,其 6 个月死亡率为 100%(中位总生存期为 0.5 个月)。开放性主动脉修复是唯一潜在的治愈方法,但伴有 90 天死亡率为 26.7%(4/15)。
应向所有患者提供开放性主动脉修复联合围手术期抗生素治疗,作为唯一潜在的治愈方法。如果适用,应在成功修复主动脉后切除共存的结肠肿瘤。或者,对于不适合手术的患者,可以在姑息治疗中提供长期抗生素治疗。血管内主动脉修复仅在少数患者中进行,支架移植物感染风险较高,应作为不能手术患者的紧急干预的挽救性策略。